Halozyme expands argenx deal to cover two more drug targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 124.54 -0.29 (0.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.83 | 52 Week High | $18.39 | |||
| Open | $124.72 | 52 Week Low | $6.96 | |||
| Day High | $124.91 | P/E | N/A | |||
| Day Low | $121.62 | EPS | $-0.58 | |||
| Volume | 5,097,773 | |||||
